Exelixis, Bristol Myers Squibb combo extends survival in kidney cancer

Exelixis, Bristol Myers Squibb combo extends survival in kidney cancer

STAT Plus: Drug combination from Exelixis and Bristol Myers Squibb extends survival in kidney cancer

By MATTHEW HERPER

MEL EVANS/AP

A combination of Cabometyx and Opdivo improved the survival of previously untreated patients with kidney cancer compared to an older treatment, sunitinib.

READ MORE